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Abstract
Background: The aims of this study were to determine the time course of improvements in attention deficit
hyperactivity disorder (ADHD) clinical symptoms and neurocognitive function in a realistic clinical setting, and the
differences in ADHD symptom improvement using different classifications of ADHD subtypes.
Methods: The Child Behavior Checklist (CBCL) was completed by parents of ADHD children at the initial visit. The
computerized Continuous Performance Test (CPT), Swanson, Nolan, and Pelham, and Version IV Scale for ADHD
(SNAP-IV), and ADHD Rating Scale (ADHD-RS) were performed at baseline, one month, three months, and six
months later, respectively. Patient care including drug therapy was performed at the discretion of the psychiatrist.
The ADHD patients were divided into DSM-IV subtypes (Inattentive, Hyperactive-impulsive and Combined type),
and were additionally categorized into aggressive and non-aggressive subtypes by aggression scale in CBCL for
comparisons.
Results: There were 50 ADHD patients with a mean age of 7.84 ± 1.64 years; 15 of them were inattentive type, 11
were hyperactive-impulsive type, and 24 were combined type. In addition, 28 of the ADHD patients were grouped
into aggressive and 22 into non-aggressive subtypes. There were significant improvements in clinical symptoms of
hyperactivity and inattention, and impulsivity performance in CPT during the 6-month treatment. The clinical
hyperactive symptoms were significantly different between ADHD patients sub-grouping both by DSM-IV and
aggression. Non-aggressive patients had significantly greater changes in distraction and impulsivity performances in
CPT from baseline to month 6 than aggressive patients.
Conclusions: We found that ADHD symptoms, which included impulsive performances in CPT and clinical
inattention and hyperactivity dimensions, had improved significantly over 6 months under pragmatic treatments.
The non-aggressive ADHD patients might have a higher potential for improving in CPT performance than
aggressive ones. However, it warrant further investigation whether the different classifications of ADHD patients
could be valid for predicting the improvements in ADHD patients’ clinical symptoms and neurocognitive
performance.
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Attention deficit hyperactivity disorder (ADHD), which
occurs in 3% to 10% of school-age children, is one of
the most common child and adolescent psychiatric dis-
orders [1,2]. ADHD in children has been shown to have
a significantly negative influence on global aspects of
academic performance, family function, and interperso-
nal relationships [3,4]. Several studies have demon-
strated that ADHD is associated with cognitive
impairments on neuropsychological tests [5,6]. Because
of the heterogeneity of symptoms in ADHD, the history
of classifying ADHD is rife with debate.
Early concerns about ADHD classification were raised
over whether it is a broad sense of conduct disorder or
a distinct externalizing category [7]. Some studies have
emphasized the importance of distinguishing between
children with ADHD alone and those with a combina-
tion of ADHD symptoms and aggression [8]. Aggression
appeared to be a useful means of subtyping ADHD chil-
dren with respect to behavior, cognitive performance,
family function and later outcome [9,10]. Different
responses of aggressive and non-aggressive ADHD chil-
dren to methylphenidate (MPH) were noted in beha-
vioral and laboratory measures [11,12].
Based on the current Diagnostic and Statistical Manual,
Fourth Edition (DSM-IV) [3], ADHD is categorized into
3 subtypes, including inattentive type, hyperactive-impul-
sive type, and combined type, according to the predomi-
nant clinical manifestations of inattention, hyperactivity,
and impulsivity. The validity of DSM-IV ADHD predo-
minantly inattentive and combined types has been
debated for decades [13,14]. Besides the clinical manifes-
tations, differences in externalizing problems and impair-
ments in school work and peer-related activity between
subtypes have also been reported [15]. The effects of
methylphenidate on the neuropsychological profiles of
subtypes of ADHD patients are still controversial [16,17].
Of the stimulant medications, MPH is the most widely
used in the pharmacological management of children
with ADHD [18]. Some studies have demonstrated the
acute neuropsychological effects of MPH in ADHD
patients [19,20]. Acute MPH quickens response on a
reaction time task and enhanced performance on some
aspects of non-executive functioning [20]. It has also
been noted that MPH increased the time spent on-task,
and reduced time spent in distracted, impulsive, and
random response states [19]. The temporal and sustain-
ing effects on ADHD behavioral symptoms were signifi-
cant after 4 months of MPH treatment [21]. The
famous NIMH multi-model treatment study of ADHD
(MTA) reported significant differences in hyperactive-
impulsive symptoms with medication treatment within
14 months [22]. However, relatively few studies have
investigated the long-term course of improvements in
ADHD symptoms and their neurocognitive function; as
well as the differences between ADHD subtypes.
Therefore, the aims of the present study were to
determine: First, whether there are sustainable improve-
ments in ADHD clinical symptoms and neurocognitive
function in realistic clinical settings. Second, whether
the differences in ADHD clinical symptoms and neuro-
cognitive functions between ADHD subtypes exist along
with the course of treatment. And, whether there were
differences in improvements in ADHD symptoms
between different classifications of ADHD patients.
Methods
Study participants
This observational-prospective study was conducted at
the Child and Adolescent Psychiatry Out-patient
Department of Chang Gung Memorial Hospital, Kee-
lung, from May 2008 to June 2009. The study was
approved by the Institutional Review Board (IRB) of
Chang Gung Memorial Hospital. We recruited patients
aged between 6 and 12 years old who met the criteria
for ADHD outlined in the DSM-IV [3]. The diagnosis
was made by a child psychiatrist in a structured inter-
view using the Kiddie Epidemiologic Version of the
Schedule for Affective Disorders and Schizophrenia (K-
SADS-E) [23]. Development of the Chinese K-SADS-E
was completed by the Child Psychiatry Research Group
in Taiwan [24]. Patients were examined by child psy-
chiatrists and excluded from the study if they had a his-
tory of major physical or psychiatric disease (such as
pervasive developmental disorder, bipolar disorder,
major depression, anxiety disorder, or psychosis), a his-
tory of substance abuse, or mental retardation. Included
patients were either newly diagnosed with ADHD or
had an existing diagnosis but had not taken medication
for ADHD during the previous 6 months or more.
Clinical Measures
Patients were interviewed by a clinician using the
ADHD Rating Scale (ADHD-RS) and a computerized
Continuous Performance Test (CPT). The social and
behavioral competence and ADHD symptoms of
patients were evaluated with the Child Behavior Check-
list (CBCL), Swanson, Nolan, and Pelham, and Version
IV Scale for ADHD (SNAP-IV), which the parents of
the patients completed.
The Child Behavior Checklist (CBCL)
is a questionnaire completed by parents and teachers that
evaluates the social and behavioral competence in the
past 6 months of children aged between 4 and 16 years
old [25,26]. The CBCL contains eight subscales: depres-
sion/anxiety, thought/obsessive, somatic complaint, social
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quency, internalizing behavior, and externalizing beha-
vior. A T-score of 50 for each scale indicates average
functioning in reference to other children of the same
age and gender, and every 10 points represents one stan-
dard deviation [25,27].
The ADHD-Rating Scale-parent (ADHD-RS)
by DuPaul et al. (1998) is a validated instrument with
which clinicians assign ratings on the basis of information
from the parent(s) and child [28]. It is an 18-item checklist
derived from the 18 criteria outlined in the DSM-IV for
diagnosing ADHD. Each of the items has a 4-point Likert
scale scoring from 0 to 3 points (0 = never or rarely, 1 =
sometimes, 2 = often and 3 = very often). ADHD-RS pro-
vides a total score (the sum of all 18 items), and can also
be divided into inattentive (odd numbered items) and
hyperactive/impulsive subscales (even numbered items).
Higher scores indicate a greater severity of ADHD. The
scale is reported to have good inter-rater reliability [29].
The Swanson, Nolan, and Pelham, and Version IV Scale
(SNAP-IV)
is a 26-item questionnaire in a 4-point Likert scale that
is used to evaluate ADHD symptoms and severity, and
it is completed by parents and teachers [30,31]. The 26
items include 18 for ADHD symptoms (9 for inattentive,
9 for hyperactive/impulsive) and 8 for oppositional defi-
ant disorder (ODD) symptoms as defined in the DSM-
IV. Each item is scored on a 0-3 scale similar to the
ADHD-RS (0 = not at all, 1 = just a little, 2 = quite a
bit and 3 = very much). The SNAP-IV consists of Inat-
tention, Hyperactivity/Impulsivity, and Oppositional
subscales [30,31]. The Chinese version of the SNAP-IV
was reported to have satisfactory levels of reliability and
concurrent validity [32].
Continuous Performance Tests (CPT)
The computerized CPT involves the presentation of tar-
get and non-target stimuli. The test runs for 14 minutes
and primarily assesses attention and impulse control
[33,34]. Briefly, participants are required to respond to
the stimuli on a computer screen by pressing a space
bar for every letter except for the letter “X.” Multiple
dependent measures exist, including Omissions, Com-
missions, Response Time, Variability of Standard Error,
and Detectability (D’). The Confidence Index (percen-
tile) integrates all CPT data obtained to provide a
chance out of 100 that a significant attention problem
exists [33,34]. In terms of the reliability of Conners’
CPT II, the pill-half reliability is 0.66-0.95, and test-ret-
est reliability after 3 months is 0.55-0.84 [35].
Study Procedure
This investigation comprised a 24-week, non-rando-
mized, observational, prospective study. At visit 1 (base-
line), each ADHD patient performed the CPT at around
9:00 AM; this took place in a room dedicated to testing
so that test condition variability was minimized. The
CBCL and SNAP-IV were completed by the patients’
p a r e n t s ,a n dA D H D - R Sr a t i n g sw e r em a d eb yac h i l d
psychiatrist. At visit 2 (one month from baseline),
patients performed the CPT at 9:00 AM, around 1 to 2
hours after they had taken MPH. The SNAP-IV was
completed by the patients’ parents, and ADHD-RS rat-
ings were made by the same rater. At visit 3 (3 months
from baseline) and visit 4 (6 months from baseline), the
same procedure as visit 2 was repeated.
Subjects were prescribed MPH at a dose range of 5 to
15 mg/day at visit 1 (V1), based on the severity of their
clinical symptoms, and their age, height and body
weight. Other concomitant medications were not
allowed. Patients were advised to take MPH at least on
weekday, but drug holiday was permitted. We confirmed
the drug compliance at each visit according to the
reports of patients’ parents and the remnant drug. To
ensure the study reflected real-life clinical practice,
patient care was performed at the discretion of the psy-
chiatrist. Modification of the MPH dose could take
place at visit 2 (V2), visit 3 (V3) or visit 4 (V4). No
treatment instructions were given other than that the
psychiatrist should manage the subjects per their usual
practice. Follow-up of the subjects was not limited by
the study’s schedule of assessments.
Statistical Analyses
The data were analyzed with the statistical software
package SPSS, Version 16. Variables are presented as
either mean ± standard deviation (SD) or frequency.
The ADHD patients were divided into DSM-IV sub-
types (Inattentive type, Hyperactive-impulsive type, and
Combined type), and were also categorized into aggres-
sive and non-aggressive subtypes, based on the aggres-
sion scale of the CBCL, with a cutoff point of 60. Chi-
square was used to compare the rate of lost to follow-
up between subtypes. The Student’s t-test or One-way
analysis of variance (ANOVA) was used to compare the
demographic data and the CBCL, SNAP-IV, ADHD-RS,
and CPT scores between ADHD subtypes.
Patients with a baseline assessment and at least 1 fol-
low-up assessment were included in the efficacy ana-
lyses. Missing data were accounted for using the
method of last observation carried forward (LOCF). The
ADHD measures, except oppositional scores of SNAP-
IV, were reduced by means of a principal components
analysis (PCA) with a set of weights for a composite
ADHD score for each subject. The composite score for
each factor and oppositional scores of SNAP-IV were
applied to the analysis for repeated-measure analysis of
variance (ANOVA), followed by a post-hoc Least Signifi-
cant Difference (LSD) test. We investigated the extent of
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scores for each factor between ADHD subtypes, also by
repeated-measure analysis of variance (ANOVA), using
average MPH dosage/body weight during 6 month as a
covariate. The hypothesis that there is a differential
change over 6 months would be supported by significant
subtype × visit interactions on dependent measures. The
factors which showed a significant interaction between
subtypes and visits were taken into further analyzed.
The changes from the baseline to the endpoint of these
factors were computed, and the Student’s t-test was
applied for examine the significant differences of these
changes between subtypes.
Two-tailed p values < 0.05 were considered statisti-
cally significant.
Results
There were 50 ADHD patients (40 boys and 10 girls)
with a mean age of 7.84 ± 1.64 years. Fifteen of them
were inattentive type, 11 were hyperactive-impulsive
type, and 24 were combined type. Using a cutoff point
of 60 on the aggression scale of the CBCL, patients were
also categorized into aggressive and non-aggressive sub-
types: 28 into the aggressive subtype and 22 into the
non-aggressive subtype. There was no significant differ-
ence in the categorization rates of patients with aggres-
sion between the DSM-IV subtypes. Table 1 presents
and compares the demographic data and ADHD symp-
tom measurements of the CBCL, SNAP-IV, ADHD-RS
and CPT between DSM-IV subtypes at baseline, and
which between aggressive and non-aggressive patients at
baseline are displayed in Table 2.
Among the 50 ADHD patients at the initial visit, 42,
33, and 30 patients remained in the study at visit 2, 3,
and 4, respectively. The reasons for premature disconti-
nuation were adverse events (N = 3), non-compliance
(N = 4), withdrawal of consent (N = 2), and lost to fol-
low-up (N = 11). There were no significant differences
Table 1 Demographic data and ADHD symptoms measurements for ADHD patients with DSM-IV subtypes at baseline
Inattentive
type
(N = 15)
Hyperactive-
impulsive type
(N = 11)
Combined
type
(N = 24)
Test
statistic
P value
Gender n(%) n(%) n(%) 0.282
Male 10 (66.7) 9 (81.8) 21 (87.5) 2.53
Female 5 (33.3) 2 (18.2) 3 (12.5)
Mean(SD) Mean(SD) Mean(SD)
Age (years) 8.1 (1.8) 7.5 (1.6) 7.3 (1.5) 1.13 0.332
Height (cm) 130.5 (10.9) 127.8 (9.7) 126.5 (8.4) 0.82 0.445
Weight (kg) 29.5 (7.5) 27.7 (7.0) 26.7 (6.2) 0.77 0.467
CBCL
Hyperactive 69.0 (12.4) 61.6 (8.2) 66.7 (8.3) 1.94 0.155
Aggression 63.3 (10.3) 64.6 (7.4) 59.3 (8.6) 1.69 0.196
Delinquency 65. 7(11.9) 61.1 (9.8) 61.8 (10.9) 0.74 0.485
SNAP-IV
Inattentive 17.3 (3.8) 14.9 (4.4) 17.5 (4.2) 1.60 0.212
Hyperactive
a 13.3 (5.8) 17.5 (4.7) 17.5 (4.6) 3.77 0.030
Oppositional 11.3 (5.8) 12.0 (4.8) 9.6 (4.4) 1.06 0.355
ADHD-RS
Total score 30.8 (4.5) 31.8 (5.4) 34.3 (5.7) 2.17 0.125
Inattention
b 16.5 (2.3) 12.7 (3.1) 17.9 (3.3) 11.11 <0.001
Hyperactivity
c 14.3 (3.8) 19.2 (3.2) 16.4 (4.2) 4.88 0.012
CPT
Confidence Index 53.7 (21.6) 58.3 (16.5) 63.4 (24.0) 0.91 0.408
Omission 53.4 (10.3) 53.3 (10.7) 63.7 (30.4) 1.32 0.277
Commission 46.4 (10.5) 47.4 (12.7) 48.3 (10.8) 0.13 0.877
Hit RT 57.6 (13.3) 52.9 (9.9) 58.7 (15.2) 0.70 0.502
Hit RT SE 54.3 (10.4) 54.8 (8.8) 60.5 (12.6) 1.78 0.181
Variability 53.1 (8.9) 54.4 (8.9) 58.4 (10.7) 1.52 0.230
Detectability 47.9 (8.7) 50.4 (13.2) 51.0 (8.2) 0.48 0.623
Response Style 50.7 (11.7) 47.5 (6.8) 54.0 (12.0) 1.39 0.258
CBCL = The Child Behavior Checklist; SNAP-IV = the Swanson, Nolan, and Pelham, and Version IV Scale; ADHD-RS = ADHD Rating Scale; CPT = The Computerized
Continuous Performance Test; RT = reaction time; SE = Standard Error.
a H > I, C > I, H≈C;
b I > H, C > H, I≈C;
c H > I, C≈H, I≈C
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ADHD patients (p = 0.905), or between aggressive and
non-aggressive patients (p = 0.606). All patients were
drug-free at visit 1 (baseline). The mean dose of MPH
was 9.87 ± 5.09 mg (0.37 ± 0.20 mg/kg) at visit 2, 14.88
± 6.97 mg (0.48 ± 0.29 mg/kg) at visit 3, and 13.00 ±
7.52 mg (0.46 ± 0.24 mg/kg) at visit 4, respectively.
To condense the number of ADHD measures and
reduce type I errors, a principal components analysis
was performed. Four factors yielding eigenvalues greater
than 1.00 were retained for varimax rotation. The
weights for the measures of each factor are listed in
Table 3. The resultant factors were labeled on the basis
of their clinical meaning: CPT distraction (factor 1),
CPT impulsivity (factor 2), clinical hyperactivity (factor
3), and clinical inattention (factor 4). These 4 factors
had eigenvalues of 3.99, 2.21, 1.44, and 1.16, respec-
tively, and accounted for 79.93% of the total matrix
variance.
During the 6-month treatment, there were significant
improvements in CPT impulsivity (F = 17.22, p < 0.001),
clinical hyperactivity (F = 19.85, p < 0.001), and clinical
inattention (F = 26.06, p < 0.001). However, CPT dis-
traction was not improved (F = 0.80, p = 0.497), and
there were no significant differences between any paired
visits. For the rest three factors aforementioned, the
trends of changes were the same during 6 months.
There were significant improvements from V1 to V2,
and V2 to V3, but no significant differences from V3 to
V4. The oppositional scores of SNAP-IV significantly
Table 2 Demographic data and ADHD symptoms measurements for ADHD patients with aggression and without
aggressive at baseline
Aggressive
(N = 28)
Non-aggressive
(N = 22)
Test
statistic
P value
Gender n (%) n (%) 0.263
Male 21 (75.0) 19 (86.4) 0.48
Female 7 (25.0) 3 (13.6)
ADHD subtype 2.35 0.308
Inattentive 9 (32.1) 6 (27.3)
Hyperactive-impulsive 8 (28.6) 3 (13.6)
Combined 11 (39.3) 13 (59.1)
Mean (SD) Mean (SD)
Age (years) 7.6 (1.8) 7.6 (1.4) 0.06 0.955
Height (cm) 128.6 (8.6) 127.1 (10.6) 0.54 0.595
Weight (kg) 27.5 (5.7) 28.1 (8.0) -0.29 0.776
CBCL
Hyperactive 69.8 (8.8) 61.7 (9.3) 3.12 0.003
Aggression 68.1 (6.0) 53.6 (4.7) 9.42 < 0.001
Delinquency 69.8 (8.0) 54.0 (7.0) 7.31 < 0.001
SNAP-IV
Inattentive 17.4 (4.8) 16.2 (3.3) 1.05 0.301
Hyperactive 17.7 (4.5) 14.4 (5.7) 2.32 0.025
Oppositional 12.9 (4.2) 7.8 (4.3) 4.24 < 0.001
ADHD-RS
Total score 33.5 (6.0) 31.7 (4.6) 1.12 0.268
Inattention 15.7 (3.3) 17.1 (3.8) -1.41 0.165
Hyperactivity 17.8 (4.0) 14.6 (3.8) 2.83 0.007
CPT
Confidence Index 57.3 (21.1) 62.0 (22.9) -0.76 0.450
Omission 57.5 (20.2) 59.3 (26.0) -0.27 0.786
Commission 47.8 (11.6) 47.2 (10.2) 0.19 0.851
Hit RT 53.8 (11.1) 61.3 (15.4) -1.98 0.053
Hit RT SE 54.8 (10.7) 60.6 (11.7) -1.84 0.072
Variability 54.6 (10.3) 57.7 (9.2) -1.11 0.275
Detectability 49.3 (10.1) 50.7 (9.0) -0.53 0.598
Response Style 49.0 (6.9) 54.9 (14.4) -1.89 0.065
CBCL = The Child Behavior Checklist; SNAP-IV = the Swanson, Nolan, and Pelham, and Version IV Scale; ADHD-RS = ADHD Rating Scale; CPT = The Computerized
Continuous Performance Test; RT = reaction time; SE = Standard Error.
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were significant differences from V1 to V2, and V3 to
V4.
In terms of the differences between DSM-IV subtypes,
Figure 1 summarizes the results of changes over time
for each of the four dependent factors. For CPT distrac-
tion, CPT impulsivity, and clinical inattention, there was
no significant difference between the subtypes and no
significant interaction between subtypes and visits in
these factors. For clinical hyperactivity, there was signifi-
cant difference (F = 4.11, p = 0.024) between subtypes,
but no significant interactions between DSM-IV sub-
types and visits.
For the differences between aggressive and non-
aggressive patients, the res u l t sw e r em o r ed i v e r s ei n
each factor. Figure 2 demonstrate the results of changes
over time for each of the four dependent factors. For
CPT distraction, there was no significant difference
between subtypes, but there was significant interaction
between subtypes and visits (F = 3.05, p = 0.031). The
changes from V1 to V4 in non-aggressive patients were
significantly greater than aggressive patients (t = 2.27, p
= 0.028). Similarly for CPT impulsivity, there was no
significant difference between subtypes, but there was
also significant interaction between subtypes and visits
(F = 3.53, p = 0.017). The changes from V1 to V4 in
non-aggressive patients were significantly greater than
aggressive patients (t = 2.39, p = 0.021). For clinical
hyperactivity, there was a significant difference between
subtypes (F = 7.87, p = 0.008), but no significant inter-
action between subtypes and visits. For clinical
inattention, there were neither significant differences
between subtypes nor an interaction between subtypes
and visits.
Discussion
The results of our study showed significant improve-
ments in clinical hyperactivity, inattention, and CPT
impulsivity composited scores, but not in CPT distrac-
tion scores during the 6 months of real-world clinical
treatment. There were significant differences in clinical
hyperactivity between ADHD patients sub-grouping
both by DSM-IV subtype and by CBCL aggressive scale.
There were no interactions between DSM-IV subtypes
and visits in these 4 dimensions of clinical symptoms
and cognitive performance among ADHD patients.
Nevertheless, the interactions between sub-grouping by
CBCL aggressive scale and visits were significant in the
CPT performance.
Optimal performance on the CPT is achieved by
responding quickly and not making mistakes [36]. Some
studies suggested that CPT performance measures
appeared to be highly correlated to the constellation of
ADHD symptoms [37]. In the traditional understanding
of how CPT results relate to ADHD behaviors, errors of
commission and omission are assumed to reflect impul-
sivity and symptoms of inattention, respectively [37,38].
In general, CPT is a relatively objective index which
showed less placebo effects and rating bias [39]. CPT
performances of children with ADHD significantly
i m p r o v ea f t e ras i n g l ed o s eo fM P H[ 1 9 ] .W es u g g e s t
that the CPT impulsivity response improved along with
Table 3 The structure of factors produced by principal components analysis of ADHD measures
a,b
Factor 1
(CPT
distraction)
Factor 2
(CPT
impulsivity)
Factor 3
(Clinical
hyperactivity)
Factor 4
(Clinical
inattention)
SNAP-IV
Inattention 0.08 0.07 0.36 0.79
Hyperactivity 0.09 0.08 0.85 0.29
ADHD-RS
Inattention 0.19 0.11 -0.06 0.89
Hyperactivity 0.18 0.06 0.93 -0.04
CPT
Omission 0.73 -0.06 0.19 0.34
Commission -0.14 0.96 0.05 0.04
Hit RT 0.76 -0.43 -0.06 0.11
Hit RT SE 0.93 0.08 0.11 0.15
Variability 0.84 0.25 0.20 0.12
Detectability 0.21 0.90 0.09 0.16
Response style 0.68 0.02 0.03 -0.06
aRotation Method: Varimax with Kaiser Normalization.
bAbsolute value of factor loadings greater than 0.50 for each variable in bold face type.
CPT = The Computerized Continuous Performance Test; SNAP-IV = the Swanson, Nolan, and Pelham, and Version IV Scale; ADHD-RS = ADHD Rating Scale; RT =
reaction time; SE = Standard Error.
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cal setting, but the distraction response did not.
Differences in the neuropsychological profiles and
effects of MPH between DSM-IV subtyping ADHD
patients have been reported [16,17]. Chhabildas et al.
(2001) showed similar profiles of impairment on neu-
ropsychological measures in hyperactive and non-hyper-
active patients [16]. Gorman et al. demonstrated that
MPH ameliorated task-incompatible behavior and atten-
tion comparably in both ADHD subtypes, but hyperac-
tivity and aggression were reduced largely in hyperactive
types [17]. ADHD subtypes differed along with symptom
severity in childhood, but these differences were no
longer significant in adolescents [40]. In our study, there
were no interactions of DSM-IV subtypes with these 4
dimensions of clinical symptoms and cognitive perfor-
mance among ADHD patients. The discriminating valid-
ity for the effectiveness of MPH by ADHD sub-grouping
by DSM-IV was not supported.
Different characteristics of behavioral and neurocogni-
tive performance were investigated between aggressive
and non-aggressive ADHD patients, and classified by
the IOWA Conners or CBCL [11,12,41]. Klorman et al.
reported improvement in ADHD behavior and accuracy
and speed on the CPT for both groups under MPH
treatment [41]. Barkley et al. demonstrated a similar
drug response in these two groups, however, the non-
aggressive patients had linear decrease in error rates of
CPT commission parameter [11]. Matier et al. reported
that both ADHD groups had a significant decrease in
attention, but the activity level decreased only in the
non-aggressive ADHD group, after medication [12]. In
our study, non-aggressive ADHD patients showed a
greater degree of improvement in CPT performance
from medication than aggressive ones. These results
might indicate that non-aggressive ADHD patients had
a higher potential for improving in neurocognitive func-
tion than aggressive ones.
These results also supported the hypothesis that
aggressive and non-aggressive ADHD patients might
have different underlying determinants. Diminished cen-
tral serotonergic (5-HT) activity has been linked to
impulsivity and aggression [42]. Catecholaminergic (CA)
mechanisms have been more strongly implicated as
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Figure 1 Changes in ADHD symptom composite scores between DSM-IV subtypes of ADHD patients during 6 months of real-world
clinical treatment. There were no significant differences between DSM-IV subtypes in CPT distraction (a), CPT impulsivity (b), and clinical
inattention (d). For clinical hyperactivity (c), there was significant difference (F = 4.11, p = 0.024) between subtypes (H>I, C>I, H˜C). There were no
significant interactions between DSM-IV subtypes and visits in these four composite scores. I = inattentive type; H = hyperactive-impulsive type;
C = combined type.
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Page 7 of 10neurobiological factors of ADHD, especially in the dopa-
minergic system [43]. The mechanism of MPH which
i n h i b i t st h er e u p t a k eo fd o p a m i n ei n c r e a s e ss y n a p t i c
dopamine and dopaminergic neurotransmission [44].
Thus, the primary effect of MPH on central CA
mechanisms might have a significantly greater impact
on the non-aggressive ADHD patient, whose deficits are
hypothesized to be mediated by CA. The aggressive
ADHD patient, whose deficits are hypothesized to be
partly related to 5-HT mechanisms, had less response to
MPH [12].
The course of ADHD symptom improvement has
been demonstrated in some studies. However, most of
these studies focused on the acute effects of MPH on
neuropsychological tests [19,20]. Other studies that
investigated the sustainable effects of MPH on ADHD
behavioral symptoms often simply compared the end-
point with the baseline of the studies [21,22]. In our
s t u d y ,w ep r o v i d e dt h et i m ec o u r s eo fA D H Ds y m p t o m
improvement with MPH treatment in the real world set-
ting. The hyperactive-impulsive, inattentive and opposi-
tional ADHD clinical symptoms were significantly
improved during 6 months. The results are generally
identical to the previous literature [22], as well as clini-
cal experience of many child psychiatrists.
Limitations
Some limitations of this study need to be considered.
First, this was an open labeled, non-randomized study,
so the placebo effects, rating bias, and reporting bias
could not be ruled out. In addition, there was no data of
ADHD patients on placebo or non-medicated for com-
parison; hence, we could not certainly justify these
results derived from effects of MPH or time. Second,
the aggressive and non-aggressive ADHD patients were
roughly divided by the aggressive behavior scales of the
CBCL with a cutoff point of 60. A suitable index has
been suggested for two standard deviations above the
normal mean on the Aggressive scale (T score > 70)
[11]. However, the clinically useful cutoff point of 60,
instead of 70, was effective in discriminating between
ADHD patients with and without comorbid diagnoses
[45]. Racial and ethnic differences in psychopathology
and symptom severity have been reported [46]. Only 8
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Figure 2 Changes in ADHD symptom composite scores between aggressive and non-aggressive ADHD patients during 6 months of
real-world clinical treatment. There was a significant difference in clinical hyperactivity (g) between aggressive subtypes (F = 7.87, p = 0.008).
There were significant interactions between aggressive subtypes and visits in CPT distraction (e) (F = 3.05, p = 0.031) and CPT impulsivity (f) (F =
3.53, p = 0.017). There was neither significant difference in clinical inattention (h) between subtypes, nor interactions between subtypes and
visits in this factor.
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Page 8 of 10subjects in our study had a T score above 70 on the
aggressive scale of the CBCL. Thus, we finally chose a
cutoff point of 60 on the aggressive scale to subdivide
the ADHD patients into aggressive and non-aggressive
subtypes. Furthermore, the correlation of aggression and
hyperactivity might hinder the distinguishability in pre-
dicting outcome, so there might be a more valid way to
make subgroups. Third, the treatment procedure was
not standardized, so there was a possible confounding
effect from the MPH dosage, although MPH doses/body
weight was used as a covariate in the analyses. Finally,
t h es a m p l es i z eo fo u rs t u d yw a sn o ts u f f i c i e n t l yl a r g e ,
so the study might not have adequate statistical power
to detect possible differences in ADHD symptoms and
CPT performance between ADHD subtypes. Meanwhile,
the dropout rate may have reduced the statistical power
and influenced the results. Caution should be taken in
applying the results to clinical practice.
Conclusions
While having limitations, our study has strengths relative
to studies on similar topics. First, we used longitudinal
evidence of changes in ADHD symptoms, rather than a
cross-sectional observation or an acute response to
MPH. Second, we measured many dimensions of ADHD
symptomatology, with scores derived from information
provided by the patients’ parents (SNAP-IV) and clinical
observers (ADHD-RS), and from performance on a neu-
rocognitive test (CPT). Last, we used different categories
in comparing ADHD symptom improvements.
We suggest ADHD symptoms, which include impul-
sivity performance in the CPT and clinical inattention
and hyperactivity dimensions, were significantly
improved during 6 months in realistic clinical settings.
The non-aggressive ADHD patients might have a higher
potential for improving in CPT performance than
aggressive ones. However, it warrant further investiga-
tion whether the different classifications of ADHD
patients could be valid for predicting the improvements
in ADHD patients’ clinical symptoms and neurocogni-
tive performance.
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